雷贝拉唑、奥美拉唑治疗老年性反流性食管炎的临床疗效观察

目的比较雷贝拉唑、奥美拉唑在治疗老年性反流性食管炎的临床疗效。方法选择2008年1月1日～2011年4月30日诊断为反流性食管炎的门诊老年患者(年龄≥60岁)201例,随机分为两组(治疗组A组和对照组B组),均经病史、内镜检查排除继发性反流性食管炎,确诊基础上进行随机分组治疗。A组104例予以雷贝拉唑20mgqd,莫沙比利5mgtid,铝碳酸镁1gtid;B组97例予以奥美拉唑20mgqd,莫沙比利5mgtid,铝碳酸镁1gtid,均以30d为一个疗程。治疗完成后进行评价。结果治疗结束时,雷贝拉唑组较奥美拉唑组的内镜改善明显,有显著差异性并有统计学意义(P<0.05),但症状改善无差异性;两组病例均未发生严重药物副作用。结论 A组予以雷贝拉唑、莫沙比利、铝碳酸镁治疗反流性食管炎在内镜改善方面较B组疗效更好,但临床症状改善无差异性。

Objective To compare rabeprazole,omeprazole in the treatment of senile reflux esophagitis clinical efficacy.Methods Hospital January 1,2008-April 30,2011 diagnosis of reflux esophagitis outpatient elderly patients（aged ≥60 years） 201 patients were randomly divided into two groups（treatment group A and control groups group B）,were confirmed by medical history,endoscopic examination to exclude secondary reflux esophagitis,diagnosed on the basis of randomized treatment.A group of 104 cases to be rabeprazole 20mg qd,mosapride 5 mg tid,aluminum magnesium carbonate 1g tid;B 97 patients toomeprazole 20mg qd,mosapride 5 mg tid,aluminum magnesium carbonate 1g tid,are 30d as a course.Evaluation after treatment is completed.Results The end of treatment,omeprazole rabeprazole group than in the endoscopic group improved significantly,and there is a significant difference was statistically significant（P0.05）,but no differences in symptom improvement;two groups of patients did not occur serious side effects.Conclusion A group to rabeprazole,mosapride,aluminum,magnesium carbonate treatment of reflux esophagitis,endoscopic improvement in efficacy and better than in group B,but no differences in clinical improvement.